替考拉宁、万古霉素、苯唑西林及其他抗菌药物对革兰氏阳性球菌血流感染分离株的体外活性比较
Comparative in vitro activities of teicoplanin, vancomycin, oxacillin, and other antimicrobial agents against bacteremic isolates of gram-positive cocci.
作者信息
Gorzynski E A, Amsterdam D, Beam T R, Rotstein C
机构信息
Veterans Administration Medical Center, Buffalo, New York.
出版信息
Antimicrob Agents Chemother. 1989 Nov;33(11):2019-22. doi: 10.1128/AAC.33.11.2019.
Abstract
The in vitro activities of teicoplanin and vancomycin were compared with those of six other antimicrobial agents against 460 bacteremic isolates of gram-positive cocci. Teicoplanin was as active as vancomycin but less active than ciprofloxacin against staphylococci. Teicoplanin was the most potent of all agents tested against enterococci and had excellent activity against pneumococci.
摘要
将替考拉宁和万古霉素的体外活性与其他六种抗菌药物针对460株革兰氏阳性球菌菌血症分离株的活性进行了比较。替考拉宁对葡萄球菌的活性与万古霉素相当，但低于环丙沙星。替考拉宁是所有测试药物中对肠球菌效力最强的，对肺炎球菌具有优异的活性。
相似文献
1
Comparative in vitro activities of teicoplanin, vancomycin, oxacillin, and other antimicrobial agents against bacteremic isolates of gram-positive cocci.替考拉宁、万古霉素、苯唑西林及其他抗菌药物对革兰氏阳性球菌血流感染分离株的体外活性比较
Antimicrob Agents Chemother. 1989 Nov;33(11):2019-22. doi: 10.1128/AAC.33.11.2019.
2
Comparison of the in vitro antibacterial activity of teicoplanin and vancomycin against gram-positive cocci.替考拉宁与万古霉素对革兰氏阳性球菌的体外抗菌活性比较。
Drugs Exp Clin Res. 1987;13(4):225-9.
3
Comparative in vitro activity of LY146032 (daptomycin), a new lipopeptide antimicrobial.新型脂肽类抗菌药物LY146032（达托霉素）的体外活性比较
Eur J Clin Microbiol. 1987 Feb;6(1):100-3. doi: 10.1007/BF02097211.
4
Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD127,391 against blood isolates of gram-positive cocci.替考拉宁、达托霉素、雷莫拉宁、万古霉素和PD127,391对革兰氏阳性球菌血液分离株的体外活性比较
Antimicrob Agents Chemother. 1992 Jul;36(7):1570-2. doi: 10.1128/AAC.36.7.1570.
5
In vitro activities of ramoplanin, selected glycopeptides, fluoroquinolones, and other antibiotics against clinical bloodstream isolates of gram-positive cocci.瑞莫拉宁、选定的糖肽类、氟喹诺酮类及其他抗生素对革兰氏阳性球菌临床血流分离株的体外活性。
Antimicrob Agents Chemother. 1993 Apr;37(4):896-900. doi: 10.1128/AAC.37.4.896.
6
Comparative in vitro activity of teicoplanin and vancomycin against United States teicoplanin clinical trial isolates of gram-positive cocci.
Diagn Microbiol Infect Dis. 1991 Jan-Feb;14(1):29-31. doi: 10.1016/0732-8893(91)90084-s.
7
In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci.利奈唑胺对包括耐万古霉素肠球菌在内的重要革兰氏阳性菌病原体的体外活性。
Antimicrob Agents Chemother. 1999 Aug;43(8):2059-62. doi: 10.1128/AAC.43.8.2059.
8
Clinical relevance of a European collaborative study on comparative susceptibility of gram-positive clinical isolates to teicoplanin and vancomycin.一项关于革兰氏阳性临床分离株对替考拉宁和万古霉素的比较敏感性的欧洲合作研究的临床相关性。
Int J Antimicrob Agents. 1998 Nov;10(4):271-7. doi: 10.1016/s0924-8579(98)00050-8.
9
Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin.与万古霉素和替考拉宁相比，糖肽类抗生素LY333328的体外活性评估。
J Antimicrob Chemother. 1998 Feb;41(2):273-6. doi: 10.1093/jac/41.2.273.
10
In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide.新型半合成糖肽LY333328的体外抗菌活性
Antimicrob Agents Chemother. 1997 Oct;41(10):2165-72. doi: 10.1128/AAC.41.10.2165.
引用本文的文献
1
Pharmacokinetic/pharmacodynamic parameters of teicoplanin for predicting clinical outcome of glycopeptide-susceptible bacteraemia.替考拉宁的药代动力学/药效学参数对预测糖肽类敏感菌血症临床结局的作用
JAC Antimicrob Resist. 2025 Aug 21;7(4):dlaf151. doi: 10.1093/jacamr/dlaf151. eCollection 2025 Aug.
2
Usefulness of a TDM-Guided Approach for Optimizing Teicoplanin Exposure in the Treatment of Secondary Bloodstream Infections Caused by Glycopeptide-Susceptible .在治疗由糖肽类敏感菌引起的继发性血流感染中，采用治疗药物监测（TDM）指导的方法优化替考拉宁暴露的效用
Microorganisms. 2025 Jan 14;13(1):162. doi: 10.3390/microorganisms13010162.
3
Teicoplanin and vancomycin as treatment for glycopeptide-susceptible Enterococcus faecium bacteraemia: a propensity score-adjusted non-inferior comparative study.替考拉宁与万古霉素治疗糖肽类敏感粪肠球菌菌血症：倾向评分调整的非劣效性比较研究。
J Antimicrob Chemother. 2023 May 3;78(5):1231-1240. doi: 10.1093/jac/dkad079.
4
Comparison of shunt infection incidence in high-risk subgroups receiving antibiotic-impregnated versus standard shunts.接受抗生素浸渍分流管与标准分流管的高危亚组中分流感染发生率的比较。
Childs Nerv Syst. 2009 Jan;25(1):77-83; discussion 85. doi: 10.1007/s00381-008-0743-0. Epub 2008 Nov 5.
5
Penetration of teicoplanin into heart valves and subcutaneous and muscle tissues of patients undergoing open-heart surgery.替考拉宁在心脏直视手术患者心脏瓣膜、皮下及肌肉组织中的渗透情况。
Antimicrob Agents Chemother. 1997 Nov;41(11):2559-61. doi: 10.1128/AAC.41.11.2559.
6
Teicoplanin in cardiac surgery: intraoperative pharmacokinetics and concentrations in cardiac and mediastinal tissues.替考拉宁在心脏手术中的应用：术中药代动力学及在心脏和纵隔组织中的浓度
Antimicrob Agents Chemother. 1997 May;41(5):1150-5. doi: 10.1128/AAC.41.5.1150.
7
Comparative activity of teicoplanin and vancomycin against 400 penicillin susceptible and resistant Streptococcus pneumoniae. The French Study Group.替考拉宁与万古霉素对400株青霉素敏感和耐药肺炎链球菌的比较活性。法国研究小组。
Eur J Clin Microbiol Infect Dis. 1994 Jan;13(1):33-4. doi: 10.1007/BF02026121.
8
Anti-infective treatment in intensive care: the role of glycopeptides.重症监护中的抗感染治疗：糖肽类药物的作用
Intensive Care Med. 1994 Nov;20 Suppl 4:S17-22. doi: 10.1007/BF01713978.
9
Teicoplanin: 10 years of clinical experience.替考拉宁：10年临床经验
Infection. 1994 Nov-Dec;22(6):430-6. doi: 10.1007/BF01715507.
10
Treatment of bone, joint, and vascular-access-associated gram-positive bacterial infections with teicoplanin.替考拉宁治疗骨、关节及血管通路相关革兰氏阳性菌感染
Antimicrob Agents Chemother. 1990 Dec;34(12):2392-7. doi: 10.1128/AAC.34.12.2392.
本文引用的文献
1
An aminoglycoside disk sensitivity test for use with enterococci.一种用于肠球菌的氨基糖苷类药敏试验。
J Antimicrob Chemother. 1982 Nov;10(5):459-62. doi: 10.1093/jac/10.5.459.
2
Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid.环丙沙星、诺氟沙星、恶喹酸、西诺沙星和萘啶酸的抗菌活性。
Antimicrob Agents Chemother. 1984 May;25(5):633-7. doi: 10.1128/AAC.25.5.633.
3
Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.环丙沙星，一种对需氧菌和厌氧菌均有活性的喹诺酮羧酸化合物。
Antimicrob Agents Chemother. 1984 Mar;25(3):319-26. doi: 10.1128/AAC.25.3.319.
4
In vitro activity of ciprofloxacin (Bay o 9867).环丙沙星（拜耳o 9867）的体外活性。
Antimicrob Agents Chemother. 1983 Oct;24(4):568-74. doi: 10.1128/AAC.24.4.568.
5
Teichomycin: in-vitro and in-vivo evaluation in comparison with other antibiotics.替考霉素：与其他抗生素相比的体外和体内评价
J Antimicrob Chemother. 1983 May;11(5):419-25. doi: 10.1093/jac/11.5.419.
6
In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.新型喹啉衍生物Bay 09867与其他抗菌药物的体外活性比较。
Antimicrob Agents Chemother. 1983 Apr;23(4):559-64. doi: 10.1128/AAC.23.4.559.
7
Ciprofloxacin: in vitro activity, mechanism of action, and resistance.环丙沙星：体外活性、作用机制及耐药性
Rev Infect Dis. 1988 May-Jun;10(3):516-27. doi: 10.1093/clinids/10.3.516.
8
High-content aminoglycoside disks for determining aminoglycoside-penicillin synergy against Enterococcus faecalis.用于确定氨基糖苷类药物与青霉素对粪肠球菌协同作用的高含量氨基糖苷类药敏纸片
J Clin Microbiol. 1988 Feb;26(2):257-60. doi: 10.1128/jcm.26.2.257-260.1988.
9
Quality control limits for teicoplanin susceptibility tests and confirmation of disk diffusion interpretive criteria.替考拉宁药敏试验的质量控制限度及纸片扩散法解释标准的确认
J Clin Microbiol. 1987 Sep;25(9):1812-4. doi: 10.1128/jcm.25.9.1812-1814.1987.
10
Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections.一项比较替考拉宁和氟氯西林治疗严重葡萄球菌感染的前瞻性随机试验的提前终止。
J Infect Dis. 1987 Feb;155(2):187-91. doi: 10.1093/infdis/155.2.187.
Zotero 插件